Dalgan

(Dezocine)

ApprovedSmall molecule

AstraZeneca

Dalgan is one of 30 small molecule programs targeting Postoperative Delirium (POD). It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Postoperative Delirium (POD)Not yet recruiting

DexamethasoneCompleted

Postoperative RecoveryRecruiting

Postoperative Delirium (POD)Preclinical

Not yet recruiting

DexamethasonePreclinical

Completed

Postoperative RecoveryApproved

Recruiting

Competition

Competitive Landscape

33 competitors in Dexamethasone

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Rayos

3 3

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

17 4

Empliciti

Bristol-Myers Squibb

Phase 3

2 5

Velcade

SShilpa Grover, MD, MPH

Phase 3

9 6

Kyprolis

VVirionyx Corporation Limited

Phase 3

6 7

Dalgan

AstraZeneca

Approved

1 8

Zyprexa

MMODAG GmbH

Phase 3

3 9

Decadron

QQuince Therapeutics S.p.A.

Phase 3

3 10

Darzalex

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalNot yet recruiting

Postoperative Delirium (POD)

NCT07768150

Q4 2028

Phase 2Not yet recruiting

Gallbladder Stones

NCT07741188

Clinical

Trials by Indication[1]

Bariatric Surgery1 trial

Use of Oxycodone in Bariatric Surgery

Unknown status·QQiang Fu·Phase 4·NCT05515822·90 enrolled

Dexmedetomidine1 trial

Effect of Dexmedetomidine for Postoperative Intravenous Patient Controlled Analgesia

Unknown status·WWeifeng Tu·Phase 4·NCT03014713·50 enrolled

Dexamethasone1 trial

The Effects of Dezocine Pretreatment on Dexamethasone Induced Perineal Irritation

Completed·GGeneral Hospital of Ningxia Medical University·N/A·NCT02768168·80 enrolled

Prevention1 trial

Dezocine for Prevention of Catheter-related Bladder Discomfort

Completed·JJian-jun Yang·Phase 4·NCT03147066·96 enrolled

Postoperative Recovery1 trial

Effect of Dezocine Combined With Sufentanil on the Quality of Postoperative Recovery and Analgesic Effect in Patients Undergoing Thoracic Surgery

Recruiting·YYangtze River Pharmaceutical Group Co., Ltd.·Phase 4·NCT06439368·210 enrolled

4 more indications

Efficacy and Safety1 trial

The Efficacy and Safety of Dezocine Pretreatment for Pain Relief in Acne Scar Treatment of Fractional CO2 Laser

Unknown status·XXijing Hospital·Phase 4·NCT05861063·105 enrolled

Patient-Controlled Analgesia1 trial

The Comparison of the Analgesic Effects of Dezocine and Sufentanil in Patient-controlled Analgesia After Laryngectomy

Completed·EEye & ENT Hospital of Fudan University·N/A·NCT06000137·129 enrolled

Postoperative Delirium (POD)1 trial

Effect of Perioperative Dezocine Administration on Postoperative Delirium in Elderly Patients Undergoing Cardiopulmonary Bypass Cardiac Surgery: A Randomized Controlled Trial

Not yet recruiting·CChinese Academy of Medical Sciences, Fuwai Hospital·Preclinical·NCT07768150·640 enrolled

Gallbladder Stones1 trial

A Multicenter, Randomized, Parallel-Group Controlled Study Evaluating the Efficacy and Safety of Anrikefon in Postoperative Pain Management in Patients Undergoing Elective Laparoscopic Cholecystectomy Under General Anesthesia

Not yet recruiting·AAffiliated Hospital of Guangdong Medical University·Phase 2·NCT07741188·144 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 29, 1989

DALGAN

NDA NDA019082

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Dezocine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dezocine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dezocine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA019082). U.S. Food & Drug Administration.
[5]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AstraZeneca

Dalgan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2028

Trials by Indication[1]

Bariatric Surgery1 trial

Dexmedetomidine1 trial

Dexamethasone1 trial

Prevention1 trial

Postoperative Recovery1 trial

Efficacy and Safety1 trial

Patient-Controlled Analgesia1 trial

Postoperative Delirium (POD)1 trial

Gallbladder Stones1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News